Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Acad Pediatr. 2014 Sep-Oct;14(5 0):S68–S75. doi: 10.1016/j.acap.2014.05.009

Table 1.

National Guidelines Identified for Review Related to NCINQ Pediatric Antipsychotic Measure Concepts

Abbreviated Name Sponsoring Organization and Guideline Title Year Population Brief Description
AACAP-AAA AACAP—Practice parameter for the use of atypical antipsychotic medications in children and adolescents23 2011 Web 5–18 y 19 recommendations on the use of atypical antipsychotics in children, rated using AACAP rating system.*
AACAP-PsyMed AACAP—Practice parameter on the use of psychotropic medication in children and adolescents24 2009 ≤18 y 13 best practice principles that underlie psychotropic medication prescribing for children (unrated).
AACAP-BP AACAP—Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder17 2007 ≤18 y, bipolar disorder 11 recommendations on the treatment of bipolar disorder in children, rated using AACAP rating system.*
AACAP-ODD AACAP—Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder18 2007 ≤18 y, oppositional defiant disorder 11 recommendations on the treatment of oppositional defiant disorder, rated using AACAP rating system.*
AACAP-SZ AACAP—Practice parameter for the assessment and treatment of children and adolescents with schizophrenia25 2001 ≤18 y, schizophrenia Recommendations are embedded within a summary of the literature on treatment of schizophrenia in children, with some recommendations rated using AACAP system.*
CAMESA CAMESA—Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children—Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth19 2011 ≤18 y, on antipsychotic Monitoring tests for children on antipsychotics are rated for SOR and SOE for 10 laboratory and 6 physical examination tests for each of 6 atypical antipsychotics, at 4 time points (baseline, 3, 6, and 12 mo) using the GRADE29,33 system (total of 384 rated recommendations).
PPWG AACAP-sponsored Preschool Psychopharmacology Working Group—Psychopharmacological treatment for very young children: Contexts and guidelines21 2007 <6 y 9 treatment algorithms for the treatment of 9 diagnoses in preschool aged children with rated recommendations for each stage of the algorithm using an adaptation of the AACAP rating system.*
TRAAY Center for the Advancement of Children’s Mental Health—Treatment recommendations for the use of antipsychotics for aggressive youth22 2003 ≤18 y, aggression 14 recommendations on the use of antipsychotics in the treatment of aggression in youth. Formal consensus methods are used and recommendations are unrated.
T-MAY Center for Education and Research on Mental Health Therapeutics—Treatment of maladaptive aggression in youth20 2012 ≤18 y, aggression 20 recommendations on the treatment of aggression in children, with ratings of SOE using Oxford Centre for EBM grading of evidence system34 and separate SOR ratings.
TX Texas Department of Family and Protective Services—Psychotropic medication utilization parameters for foster children26 2013 Foster care 9 psychotropic prescribing practices that trigger a clinical review for children in foster care in Texas (unrated).
APA-CW American Psychiatric Association—Choosing Wisely27 2013 Children and adults 5 questionable antipsychotic prescribing practices for children and adults, based on formal consensus methods (modified Delphi, >70% agreement).

NCINQ indicates National Collaborative for Innovation in Quality Measurement; AACAP, American Academy of Child and Adolescent Psychiatry; SOE, strength of evidence; and SOR, strength of recommendation.

*

AACAP rating system is used for most AACAP guidelines (see Table 2 for definitions).